Skip to main content

Table 2 Risk factors for 30-day mortality in patients treated with vancomycin or linezolid

From: Comparative-effectiveness of vancomycin and linezolid as part of guideline-recommended empiric therapy for healthcare-associated pneumonia

Risk factors Adjusted OR (95 % CI)a,b
Vancomycin versus linezolid use 2.56 (1.674.04)
Year of hospitalization, 2005-2007 0.61 (0.440.83)
Race (White) 1.13 (0.66–1.90)
Race (Black) 1.23 (0.66–2.49)
Hispanic ethnicity 0.64 (0.39–1.01)
VHA priority group 1 1.35 (0.71–2.52)
VHA priority group 2–6 0.67 (0.34–1.34)
Prior hospital admission 2.58 (1.664.12)
Outpatient intravenous antibiotics 1.00 (0.60–1.64)
>1 HCAP risk factor 0.78 (0.53–1.15)
Myocardial infarction 1.02 (0.60–1.67)
Congestive heart failure 0.78 (0.55–1.12)
Chronic obstructive pulmonary disease 0.84 (0.59–1.21)
Smoking 0.84 (0.60–1.18)
Cardiovascular medications 1.04 (0.74–1.47)
Anti-diabetic medications 1.07 (0.74–1.54)
Inhaled corticosteroids 0.63 (0.38–1.01)
Systemic corticosteroids 0.73 (0.49–1.07)
Pulmonary medications 1.40 (0.94–2.10)
Organ failure 1.18 (0.80–1.73)
Methicillin-resistant S. aureus 0.68 (0.34–1.27)
Streptococcus pneumoniae 0.75 (0.27–1.80)
  1. HCAP healthcare-associated pneumonia, VHA Veterans Health Administration, OR odds ratio, CI confidence interval
  2. aResults of multivariable logistic regression model; see text for covariates
  3. bItalics indicates statistical significance